| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Treating Metastatic Bone Cancer |
Author's Affiliation: Division of Hematology/Oncology, Cornell University Medical College, New York, New York
Requests for reprints: Roger N. Pearse, Division of Hematology/Oncology, Cornell University Medical College, 1300 York Avenue, Box 113, New York, NY 10021. Phone: 212-746-3964; Fax: 212-746-7888; E-mail: rnp2001{at}med.cornell.edu.
Bone disease in patients with multiple myeloma (MM) is characterized by uncoupled bone remodeling, evident as enhanced osteolytic resorption and decreased rather than increased bone formation. MM-triggered osteolysis follows deregulation of the receptor activator of nuclear factor
B ligand (RANKL)/osteoprotegerin cytokine axis. Inhibition of bone formation may result from the ability of MM to inhibit the function of Wnts, secreted glycoproteins critical to osteoblast development. Recent studies show how these processes may be linked.
This article has been cited by other articles:
![]() |
Y. Behl, M. Siqueira, J. Ortiz, J. Li, T. Desta, D. Faibish, and D. T. Graves Activation of the Acquired Immune Response Reduces Coupled Bone Formation in Response to a Periodontal Pathogen J. Immunol., December 15, 2008; 181(12): 8711 - 8718. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-S. Chim, C. P. Bik Yiu, and W. H. Shek Pathological Bone Fracture in Non-Hodgkin's Lymphoma J. Clin. Oncol., July 20, 2007; 25(21): 3175 - 3176. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |